MARIA ELENA GUERZONI

Dr. MARIA ELENA GUERZONI

University of Modena and Reggio Emilia, Modena, Emilia-Romagna, Italy
orcid

Research Focus & Metrics

Academic Career Length

5Years (2022-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
27 September 2022 in Children
Verified
Journal Article
Open access
PDF file
MGMARIA ELENA GUERZONI
MARIA ELENA GUERZONI
SMStefano Marchesi
Stefano Marchesi
GPgiovanni palazzi
giovanni palazzi
MLMariachiara Lodi
Mariachiara Lodi
MPMargherita Pinelli
Margherita Pinelli
Lorenzo IughettiLorenzo Iughetti
Lorenzo Iughetti
Background: Environmental factors seem to influence clinical manifestations of sickle cell disease (SCD), but few studies have shown consistent findings. We conducted a retrospective multicentric observational study to investigate the influence of environmental parameters on hospitalization for vaso-occlusive crises (VOC) or acute chest syndrome (ACS) in children with SCD. Methods: Hospital admissions were correlated with daily meteorological and air-quality data obtained from Environmental Regional Agencies in the period 2011–2015. The effect of different parameters was assessed on the day preceding the crisis up to ten days before. Statistical analysis was performed using a quasi-likelihood Poisson regression in a generalized linear model. Results: The risk of hospitalization was increased for low maximum temperature, low minimum relative humidity, and low atmospheric pressure and weakly for mean wind speed. The diurnal temperature range and temperature difference between two consecutive days were determined to be important causes of hospitalization. For air quality parameters, we found a correlation only for high levels of ozone and for low values at the tail corresponding to the lowest concentration of this pollutant. Conclusions: Temperature, atmospheric pressure, humidity and ozone levels influence acute complications of SCD. Patients’ education and the knowledge of the modes of actions of these factors could reduce hospitalizations.

1 January 2023 in Case Reports in Pediatrics
Verified
Journal Article
Open access
PDF file
MLMarco Lecis
Marco Lecis
KRKatia Rossi
Katia Rossi
MGMARIA ELENA GUERZONI
MARIA ELENA GUERZONI
IMilaria mariotti
ilaria mariotti
Lorenzo IughettiLorenzo Iughetti
Lorenzo Iughetti
Background . Lysosomal acid alpha‐glucosidase (GAA) deficiency, also known as Pompe disease, is an autosomal recessive disorder that leads to the accumulation of glycogen in lysosomes and cytoplasm, resulting in tissue destruction. Infantile‐onset GAA deficiency is characterized by cardiomyopathy and severe generalized hypotonia. Without treatment, most patients die within the first two years of life. The demonstration of reduced GAA activity, followed by sequencing of the GAA gene, confirms the disease. GAA deficiency is currently treated with enzyme replacement therapy (ERT) with improved clinical outcomes and survival. Case Presentation . We describe the case of DGAA in two siblings, in which the diagnostic time point, treatment, and outcomes were completely different. The girl was diagnosed with DGAA at the age of 6 months during investigations for poor weight gain and excessive sleepiness. The finding of severe cardiomyopathy through EKG and echocardiography led to the suspicion of storage disease, and the GAA deficiency was later confirmed by genetic analysis. The girl died of complications due to the clinical picture before starting ERT. Conversely, her younger brother had the opportunity to receive an early diagnosis and the rapid onset of ERT. He is showing a regression of cardiac hypertrophy. Conclusion . The advent of ERT improved clinical outcomes and survival in infantile‐onset PD. Its impact on cardiac function is still under study, but different reports in the literature have shown encouraging data. Early recognition of DGAA and prompt initiation of ERT is therefore crucial to prevent the progression of the disease and improve the outcomes.

25 August 2024
Verified
Preprint
Open access
PPPablo Velasco Puyó
Pablo Velasco Puyó
SCSoteroula Christou
Soteroula Christou
SCSaveria Campisi
Saveria Campisi
MRMaria A. Rodríguez-Sánchez
Maria A. Rodríguez-Sánchez
SRSara Reidel
Sara Reidel
MMMañú Pereira Maria Manu
Mañú Pereira Maria Manu
Background Despite several publications covering patients from multiple centers, no international registry covered all patients with red blood cell diseases (RBCD) affected by COVID-19. The ERN-EuroBloodNet’s registry provided real-time registration of SARS-CoV-2 patients with RBCD, promoting timely disease-specific knowledge sharing during the pandemic’s early stages. Procedures The study evaluated patient distribution, the infection across different RBBDs, and severity risk factors across similar healthcare systems, using data collected from the ERN-EuroBloodNet’s REDCap platform. Results From April 2020 to April 2023, 681 infections were recorded among 663 patients, of which 373 had transfusion-dependent thalassemia or non-transfusion-dependent thalassemia (TDT/NTDT), and 269 had sickle cell disease (SCD). SCD patients had a higher incidence of COVID-19 than those with TDT/NTDT (10.5 vs. 4.8 COVID/100 patients). Notably, 92% of the cases were mild, with neither age nor the specific RBCD affecting severity. The number of comorbidities, notably obesity and hypertension, that patients had prior to infection was associated with more severe COVID-19. During the infection, the presence of vaso-occlusive crises, acute chest syndrome, kidney failure, and ground-glass opacities on chest tomography scans were associated with a more severe clinical picture. The vaccination rate (32%) mirrored that of the general population and showed a protective effect against severe COVID-19. The observed mortality rate was 0.7%, aligning with Europe’s general population. Conclusion: SARS-CoV-2 infection in SCD and TDT/NTDT patients is mild and without higher mortality than the general population. The ERN-Eurobloodnet’s registry collaborative structure exemplifies the power of international cooperation in tackling rare diseases, especially during health emergencies